Hematology

A retrospective cohort study found that convalescent plasma treatment resulted in a meaningful improvement in the 30-day mortality rate for patients with hematologic cancer and COVID-19.

“So, what we’ve done is develop a technique, using the NAM technology, to expand those stem cells, so we can make 50 to 100-fold more stem cells, with higher reliability, and manufacture those cells for patients in need of a bone marrow transplant”

The efficacy of CYNK-001 will now be studied with patients with relapsed/refractory AML.

The phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials reported that Week 24 transfusion independence resulted in an improved overall survival for patients with myelofibrosis.

An early trial evaluated Anti-C-type lectin-like molecule-1 (CLL-1)-based CAR T cells for its safety and efficacy in improving the symptoms of pediatric patients with acute myeloid leukemia (AML).

A virtual presentation at the 2021 American Society of Clinical Oncology Annual Meeting suggested that patients with B-ALL benefit from single infusions of KTE-X19 (Tecartus).

Consider options like prophylactic medications and optimal fluid administration when giving a 4-drug regimen to treat patients with multiple myeloma, one expert says.

The FDA approved avapritinib (Ayvakit) for the treatment of adults with advanced systemic mastocytosis (AdvSM), including those with mast cell leukemia (MCL), aggressive systemic mastocytosism (ASM), or systemic mastocytosis with an associated hematological neoplasm (SM-AHN).

Discrepancies exist between actual patterns of care and recommendations based on clinical trials in adult patients with mantle cell lymphoma.

Learn how to approach palliative care discussions with both physicians and patients.

The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.

The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of patients with relapsed/refractory multiple myeloma.

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Melphalan flufenamide was noninferior to pomalidomide in patients with relapsed or refractory myeloma.

The FDA has granted priority review to the biologics license application for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA has accepted a biologics license application for ublituximab in combination with umbralisib in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Adding the antibody-drug conjugate to the frontline treatment of patients with pediatric high-risk Hodgkin lymphoma resulted in favorable clinical outcomes.

Whole-genome sequencing may hold the answers for patients with myeloma precursor conditions.

BCMA-directed CAR T-cell therapy is drastically changing the multiple myeloma treatment landscape.

The FDA has granted an accelerated approval to loncastuximab tesirine for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following 2 or more lines of systemic therapy.

A walking program dramatically increased the number of steps walked by patients being treated for hematologic malignancies.

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.

The FDA has approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

Novel therapeutics have not only boosted outcomes in myelofibrosis, but paved the way for new combination treatment strategies, too.

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.